Becton Dickinson

Becton Dickinson Competitive Intelligence & Landscape

bd.com ·

Overview

Becton Dickinson Overview

Becton Dickinson (bd.com) is a global medical technology company dedicated to advancing the world of health™ by innovating across medical essentials, connected care, biopharma systems, and interventional solutions [bd.com/en-us/about-bd/our-company]. The company focuses on developing transformative technologies, services, and solutions that optimize clinical operations and improve patient care [bd.com/en-us/about-bd/our-company].

BD supports healthcare professionals on the front lines by providing medical products, capabilities, and solutions worldwide [bd.com/en-us].

BD offers a wide array of products and solutions, including advanced hemodynamic monitoring, ambulatory surgery center solutions, BD Acute Urology, BD Hypodermic Needle and Syringe Solutions, hazardous drug safety, integrated diagnostic solutions, medication management solutions, patient safety solutions, sepsis management, and surgical solutions. Their offerings also extend to cervical cancer screening, clinical and lab support, diagnostic accuracy and efficiency, pharmaceutical microbiology, and vascular access management [bd.com]. The company targets various segments including clinicians, administrators, distributors, drug development companies, medical device manufacturers, laboratories, pharmacies, and surgical teams [bd.com].

Founded over 125 years ago, Becton Dickinson has a long history of improving medical discovery, diagnostics, and the delivery of care [investors.bd.com/company-information]. The company's headquarters are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880 [bd.com/en-us/support/contact-us].

As one of the world's largest pure-play medical technology companies, BD operates globally with more than 60,000 employees [bd.com/en-us/about-bd/our-company?activetab=1]. Their core purpose is to advance the world of health™ by driving innovation [bd.com/en-us/about-bd/our-company], with a mission to bring medical products, capabilities, and solutions to every corner of the world [bd.com/en-us].

Becton Dickinson

Becton Dickinson Weekly Intel Updates

Receive weekly intel updates about Becton Dickinson straight to your inbox.

Competitors

Becton Dickinson Competitors

Becton Dickinson (bd.com) faces competition from several key players in the healthcare technology and medical device sectors. One significant competitor is Medtronic, which offers a broad range of medical technologies similar to BD, including solutions for surgical care and patient safety. Medtronic's market positioning often emphasizes innovation in complex medical areas, directly competing with BD's diverse product portfolio [owler.com].

Another major rival is Johnson & Johnson, a diversified healthcare giant that competes with Becton Dickinson across various segments, including medical devices and diagnostic solutions [comparably.com]. Johnson & Johnson's extensive global presence and diverse product lines, from consumer health to pharmaceuticals, allow them to leverage a broad market reach, often providing comprehensive solutions that may overlap with BD's offerings.

Abbott Laboratories is also a strong competitor to Becton Dickinson, particularly in areas like diagnostics and medical devices [comparably.com, owler.com, koalagains.com]. Abbott's focus on areas such as cardiovascular health, diabetes care, and established diagnostics platforms positions them as a direct alternative for many of BD's diagnostic and monitoring solutions. Their market share and product features often make them a top contender in these specialized fields.

Baxter International is a notable competitor, particularly in the infusion therapy market, where they directly challenge Becton Dickinson's leadership [idataresearch.com, globaldata.com]. Baxter specializes in critical care products, including IV solutions and drug delivery systems, which are core areas for BD. While BD holds a significant installed base in large volume infusion pumps, Baxter remains a formidable opponent with a strong presence in various infusion therapy segments.

Finally, B. Braun also competes in the infusion therapy market against Becton Dickinson, offering a range of medical devices and solutions aimed at improving healthcare outcomes [idataresearch.com, cbinsights.com]. B. Braun emphasizes improving clinical outcomes and cost efficiency through their products and services, positioning them as a viable alternative for healthcare providers seeking solutions in areas where BD also operates, such as medication management and drug delivery.

Product & Pricing

Becton Dickinson Product and Pricing Intelligence

While specific public pricing plans, tiers, and free versus paid feature breakdowns are not explicitly detailed on Becton Dickinson's (bd.com) website, the company does provide various solutions and tools for its customers.

BD offers an Online Purchasing Account and eProcurement Solutions to streamline ordering and receiving lab essentials for its clients [https://go.bd.com/online-account]. These solutions suggest a transactional model for their medical products and services.

Customers can also access the BD Customer Care Portal, which allows them to conduct quick searches, view order statuses, and download packing lists and invoices for their orders [https://www.bd.com/en-us/support/bd-customer-portal-faqs]. Additionally, the support section of the website includes quick links for checking order status, implying a customer-specific pricing and order management system rather than publicly listed tiers [https://www.bd.com/en-us/support].

BD provides a range of advanced solutions like the BD Pyxis™ Pro Dispensing Solution, an automated dispensing system, and BD Pyxis™ Logistics Software, which is enterprise inventory management software for hospitals [https://www.bd.com/en-us/products-and-solutions/products]. The BD Pyxis™ Enterprise Server allows management of various BD Pyxis™ ES technologies and devices from a single web-accessible environment, suggesting integrated, enterprise-level solutions that would typically involve custom pricing based on scale and implementation [https://www.bd.com/en-uk/products-and-solutions/products/product-families/bd-pyxis-enterprise-server].

Furthermore, solutions like BD Pyxis™ Track & Deliver aim to improve communication and visibility of medication location, indicating specialized software and service offerings [https://www.bd.com/en-us/products-and-solutions/products/product-page.1107-00]. It's important to note that BD reserves the right to correct any errors or omissions in pricing at any time, as outlined in their direct terms and conditions of sale [https://www.bd.com/content/dam/bd-assets/bd-com/en-us/document/policy/supplier-policies/direct-terms-and-conditions-of-sale.pdf]. This flexibility in pricing suggests that specific product costs are determined through direct customer engagement and potentially vary based on volume, contracts, and customized solution bundles.

Hiring & Layoffs

Becton Dickinson Hiring and Layoffs

Becton Dickinson (bd.com) consistently offers numerous career opportunities, with over 500 job openings in the United States alone, reflecting a robust and ongoing hiring strategy [https://jobs.bd.com/en/search_jobs?fl=6252001]. The company actively recruits across various critical functions, signaling strategic investments in key growth areas within the MedTech and Life Sciences industries. Recent job postings indicate a strong focus on roles that support commercial strategy, technological advancement, and global market expansion.

Notably, Becton Dickinson is seeking talent in specialized areas such as marketing, information technology, and engineering. Examples include a "VP, Global Marketing and Strategy" [https://jobs.bd.com/en/job/le-pont-de-claix/vp-global-marketing-and-strategy/159/95243827680] and a "Sr. International Marketing Manager - Drainage Franchise" [https://jobs.bd.com/en/job/tempe/sr-international-marketing-manager-drainage-franchise/159/94213213072], highlighting an emphasis on market reach and product lifecycle management. The company is also heavily investing in its digital infrastructure and data capabilities, with openings for a "Senior Director, Commercial Data Products" [https://jobs.bd.com/en/job/franklin-lakes/senior-director-commercial-data-products/159/94701886032] and a "Director, Commercial Data Strategy & Governance" [https://jobs.bd.com/en/job/franklin-lakes/director-commercial-data-strategy-governance/159/94563690464].

Technological innovation remains a core focus, as evidenced by the recruitment for "Senior Software Engineer" [https://jobs.bd.com/en/job/san-diego/senior-software-engineer-on-site-san-diego/159/94036073888] and "Staff Software Engineer" positions [https://jobs.bd.com/en/job/irvine/staff-software-engineer/159/96261816272]. Furthermore, Becton Dickinson is expanding its sales and field support teams, with roles like "Associate Territory Manager - Colorado (Field)" [https://jobs.bd.com/en/job/colorado/associate-territory-manager-colorado-field/159/97478034432], indicating efforts to strengthen its market presence and direct customer engagement. The company also recruits for internal support, such as a "Talent Acquisition Director" [https://jobs.bd.com/en/job/franklin-lakes/talent-acquisition-director/159/94744517408] to manage its ongoing recruitment needs.

While the provided sources do not indicate any recent layoffs at Becton Dickinson, the consistent and varied job openings, including a significant number in the United States, suggest a strategy of sustained growth and investment in its workforce. The focus on marketing, IT, and engineering roles signals an emphasis on innovation, data-driven decision-making, and expanding global market penetration, aligning with their mission to advance the world of health.

Leadership

Becton Dickinson Management and Leadership Team

The leadership at BD (Becton, Dickinson and Company) is helmed by Tom Polen, who serves as chairman, chief executive officer, and president [bd.com/en-us/about-bd/our-company/polen-tom]. He leads an Executive Leadership Team that includes several key executives. Among them, Michael Feld is the executive vice president and chief revenue officer, overseeing global marketing, the BD Excellence Office, and Commercial Systems [bd.com/en-us/about-bd/our-company/michael-feld].

Betty Larson holds the position of executive vice president and chief human resources officer [bd.com/en-us/about-bd/our-company/larson-betty]. Other significant members of the executive team include Richard Byrd, who is the executive vice president and president of the Interventional Segment, responsible for its global operational, commercial, and financial performance [bd.com/en-us/about-bd/our-company/richard-byrd].

Dr. Michael Garrison is the executive vice president and president of the Medical Essentials and BioPharma Systems Segments [bd.com/en-us/about-bd/our-company/mike-garrison]. Recent appointments include Bilal Muhsin as executive vice president and president of the Future Connected Care Segment, reporting directly to Tom Polen [investors.bd.com/news-events/press-releases/detail/891/bd-appoints-bilal-muhsin-as-executive-vice-president-and-president-of-future-connected-care-segment].

The BD board of directors includes individuals such as William M. "Bill" Brown, Carrie L. Byington, M.D., R. Andrew Eckert, Gregory J. Hayes, Jeffrey W. Henderson, Robert L. Huffines, Timothy M. Ring, Bertram L. Scott, Joanne Waldstreicher, M.D., and Jacqueline Wright [investors.bd.com/corporate-governance]. These board members serve across various committees, including the Audit Committee, Human Capital Committee, Corporate Governance and Nominating Committee, Executive Committee, and Quality and Regulatory Committee [investors.bd.com/corporate-governance].

Gary DeFazio is the senior vice president and corporate secretary [investors.bd.com/sec-filings/all-sec-filings/content/0000010795-24-000096/0000010795-24-000096.pdf]. The company maintains a Corporate Governance and Nominating Committee Charter and an Executive Officer Cash Severance Policy, among other governance documents [investors.bd.com/corporate-governance/governance-documents].

Financials

Becton Dickinson Financial Performance, Fundraising, M&A

Becton Dickinson (bd.com) demonstrates a strong financial performance, with reported revenue of $21.8 billion for fiscal year 2025, marking an 8.2% increase as reported, 7.7% adjusted FXN, and 2.9% organic growth. The company also achieved adjusted diluted EPS of $14.40 in FY25, a 9.6% increase, and saw its GAAP and adjusted gross margin improve by 20 basis points [https://investors.bd.com/news-events/press-releases/detail/915/bd-reports-fourth-quarter-and-full-year-fiscal-2025-financial-results].

For the second quarter of fiscal year 2026, BD reported revenue of $4.7 billion, an increase of 5.2% as reported and 2.6% FXN. Their adjusted diluted EPS from continuing operations was $2.90. During this quarter, BD also executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt, reaffirming its revenue growth guidance and raising its full-year adjusted EPS guidance [https://investors.bd.com/news-events/press-releases/detail/958/bd-reports-second-quarter-fiscal-2026-financial-results]. Looking at the first quarter of fiscal year 2026, BD recorded $5.3 billion in revenue, reflecting a 1.6% increase as reported and 0.4% FXN [https://investors.bd.com/news-events/press-releases/detail/936/bd-reports-first-quarter-fiscal-2026-financial-results].

In terms of mergers and acquisitions, Becton Dickinson completed the acquisition of Edwards Lifesciences’ Critical Care product group on September 3, 2024, for a fair value of consideration transferred of $3.914 billion. This acquisition has been renamed BD Advanced Patient Monitoring [https://investors.bd.com/sec-filings/all-sec-filings/content/0000010795-25-000099/0000010795-25-000099.pdf]. Additionally, the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation was expected to close in Q1 FY26 [https://investors.bd.com/news-events/press-releases/detail/936/bd-reports-first-quarter-fiscal-2026-financial-results][https://news.bd.com/2026-02-09-BD-Reports-First-Quarter-Fiscal-2026-Financial-Results].

Partnerships

Becton Dickinson Partnerships, Clients and Vendors

Becton Dickinson (bd.com) actively engages in strategic partnerships and collaborations to advance healthcare solutions. Notably, BD partnered with Wellstar Health System to improve medication management and patient safety through AI-powered solutions across Wellstar's facilities [https://investors.bd.com/news-events/press-releases/detail/957/bd-and-wellstar-advance-patient-care-and-safety-with-medication-management-powered-by-ai]. Another significant collaboration involves Quest Diagnostics, with whom BD is developing, manufacturing, and commercializing flow cytometry-based companion diagnostics for cancer and other diseases [https://investors.bd.com/news-events/press-releases/detail/844/bd-quest-diagnostics-join-forces-to-develop-companion-diagnostics-for-cancer-other-diseases, https://news.bd.com/2024-07-25-BD,-Quest-Diagnostics-Join-Forces-to-Develop-Companion-Diagnostics-for-Cancer,-Other-Diseases].

BD also maintains strong relationships within the pharmaceutical and biotech sectors. The company expanded its partnership with Ypsomed, a leading injection systems developer, to create a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, compatible with Ypsomed's autoinjector platform, addressing the growing biologics market [https://investors.bd.com/news-events/press-releases/detail/930/bd-and-ypsomed-expand-partnership-to-address-rapidly-growing-biologics-market, https://news.bd.com/2026-01-21-BD-and-Ypsomed-Expand-Partnership-to-Address-Rapidly-Growing-Biologics-Market]. This builds on a previous strategic collaboration between BD and Ypsomed to advance self-injection solutions for high-viscosity biologic drugs [https://news.bd.com/2024-10-23-BD-and-Ypsomed-Collaborate-to-Advance-Self-Injection-Systems-for-High-Viscosity-Biologics]. Furthermore, BD has partnered with Suttons Creek to provide consulting, device-agnostic testing, and drug delivery expertise, assisting pharma and biotech companies in bringing combination products to market [https://news.bd.com/2026-04-27-BD-and-Suttons-Creek-Partner-to-Help-Pharma-and-Biotech-Companies-Deliver-Combination-Products-to-Market-with-Confidence].

In the realm of diagnostics, BD collaborates with Certest Biotec to expand its BD MAX™ System menu with new IVDR-certified VIASURE assays for respiratory and sexually transmitted infections [https://investors.bd.com/news-events/press-releases/detail/923/bd-expands-bd-max-system-menu-with-new-ivdr-certified-viasure-assays-in-partnership-with-certest-biotec]. For advanced research, BD has a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, focusing on deep human immune profiling and developing immune-mediated therapies through high-parameter flow cytometry [https://news.bd.com/2025-12-18-BD-and-Penn-Institute-for-Immunology-and-Immune-Health-Collaborate-to-Advance-Immunotherapy-through-Flow-Cytometry].

BD also positions itself as a trusted partner and single supplier for system integration, aiming to streamline combination product development for its clients by avoiding the complexities of working with multiple suppliers [https://www.bd.com/en-us/products-and-solutions/solutions/drug-delivery-systems/system-integration]. These extensive partnerships and integrations highlight BD's commitment to advancing healthcare through collaborative innovation and comprehensive solutions.

Events

Becton Dickinson Event Participations

Becton Dickinson (bd.com) actively participates in and hosts a variety of events, including conferences, webinars, and symposiums, to engage with healthcare professionals and share advancements in medical technology. For instance, BD is set to present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, offering insights into their global medical technology initiatives [https://news.bd.com/2026-02-23-BD-to-Present-at-Barclays-28th-Annual-Global-Healthcare-Conference].

The company is also a prominent presence at key industry conferences. They will be at the 14th NIVAS Conference 2026 in Brighton, a leading UK multidisciplinary event focused on vascular access and intravenous therapy [https://www.bd.com/en-uk/resource-and-education/event-landing-page/2026/nivas-conference-2026]. Additionally, BD will attend the Venous Symposium 2026 in New York, an international conference dedicated to vein pathology, and the Vascular Annual Meeting (VAM 2026) in Boston, showcasing the latest in vascular research and technology [https://www.bd.com/en-us/resource-and-education/event-landing-page/venous-symposium, https://www.bd.com/en-us/resource-and-education/event-landing-page/vam-bdpi].

BD further extends its educational outreach through various webinar series. They offer BD Vacutainer Specimen Management on-demand webinars covering topics from rapid serum tubes to pediatric lab challenges [https://www.bd.com/en-us/resource-and-education/event-landing-page/bd-vacutainer-specimen-management-on-demand-webinars]. The BD FACSMatters Webinar Series provides live sessions on the fundamentals of flow cytometry, featuring industry experts and practical tips for lab efficiency [https://go.bd.com/facs-matters-webinars].

Beyond specific conferences, BD also hosts and makes available recordings from past events, such as the International Hernia Symposium, focusing on surgical techniques and innovations [https://eu.bd.com/your-surgery/events/]. The BD MAX™ Events offer both online and offline opportunities to connect with the company [https://eu.bd.com/bdmaxclub/events/]. Furthermore, their customer learning portals, like the BD MAX™ Club, provide access to events, webinars, tutorials, and Q&A sessions with industry experts [https://eu.bd.com/bdmaxclub/].

BD also hosts webinars on topics like mastering safe infusion therapy, aimed at preventing errors and implementing best practices [https://eu.bd.com/iv-news/category/events-training/].

Frequently Asked Questions

What strategic areas is Becton Dickinson prioritizing for investment, based on its recent hiring trends?

Becton Dickinson's recent hiring indicates a strong focus on global market expansion, technological advancement, and data capabilities. The company is actively recruiting for roles such as VP, Global Marketing and Strategy; Senior Director, Commercial Data Products; and Senior Software Engineer, signaling strategic investments in these key growth areas within MedTech and Life Sciences.

Given the acquisition of Edwards Lifesciences' Critical Care product group and the planned combination with Waters Corporation, what is Becton Dickinson's M&A strategy emphasizing?

Becton Dickinson's M&A strategy emphasizes expanding its portfolio in critical care and strengthening its diagnostic capabilities. The acquisition of Edwards Lifesciences' Critical Care product group, now BD Advanced Patient Monitoring, for $3.914 billion, and the planned combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, suggest a focus on high-value, specialized medical technology sectors.

What does Becton Dickinson's consistent participation in and hosting of industry events, such as the Barclays Global Healthcare Conference and NIVAS, imply about its market strategy?

Becton Dickinson's consistent participation in and hosting of industry events implies a strategy focused on thought leadership, market presence, and continuous engagement with healthcare professionals. Presenting at conferences like the Barclays Global Healthcare Conference and participating in specialized events such as the NIVAS Conference and Venous Symposium allows BD to share advancements, educate the market, and strengthen relationships within key therapeutic areas.

How does Becton Dickinson's partnership with Wellstar Health System for AI-powered medication management reflect its approach to digital health transformation?

Becton Dickinson's partnership with Wellstar Health System for AI-powered medication management demonstrates its commitment to digital health transformation and patient safety. This collaboration shows BD is integrating advanced technologies like AI to optimize clinical operations and improve care delivery within healthcare facilities, moving towards connected and intelligent solutions.

What is the strategic significance of Becton Dickinson's expanded partnership with Ypsomed and collaboration with Suttons Creek?

The expanded partnership with Ypsomed and collaboration with Suttons Creek highlights Becton Dickinson's strategic focus on the rapidly growing biologics and combination product markets. By developing advanced prefillable syringes and offering consulting for drug delivery, BD is positioning itself as a key enabler for pharmaceutical and biotech companies bringing complex therapies to market.

What does the creation of the 'Future Connected Care Segment' and Bilal Muhsin's appointment as its president indicate about Becton Dickinson's long-term vision?

The creation of the 'Future Connected Care Segment' and Bilal Muhsin's appointment as its president indicate Becton Dickinson's long-term vision to expand into integrated and digitally-enabled healthcare solutions. This move suggests a strategic emphasis on evolving beyond traditional medical devices to offer more comprehensive, connected care platforms that enhance patient outcomes and operational efficiency.

How does Becton Dickinson's emphasis on online purchasing accounts and eProcurement solutions shape its customer engagement model?

Becton Dickinson's emphasis on online purchasing accounts and eProcurement solutions indicates a focus on streamlining transactional efficiency and improving customer convenience. These offerings suggest a customer engagement model that prioritizes digital self-service for ordering, tracking, and managing lab essentials, enhancing the overall procurement experience for its clients.

What does Becton Dickinson's offering of solutions like BD Pyxis™ Pro Dispensing Solution and BD Pyxis™ Enterprise Server signify about its product strategy for hospitals?

Becton Dickinson's offering of solutions like BD Pyxis™ Pro Dispensing Solution and BD Pyxis™ Enterprise Server signifies a product strategy focused on integrated, enterprise-level solutions for hospitals. These systems automate medication management and provide centralized control, indicating BD's aim to optimize hospital operations, improve patient safety, and offer comprehensive, scalable solutions for healthcare facilities.

Given its strong financial performance, including 8.2% reported revenue growth in FY25 and adjusted diluted EPS increase, where might Becton Dickinson be directing its capital allocation?

Given its strong financial performance, Becton Dickinson appears to be directing its capital allocation towards both strategic acquisitions and shareholder returns. The company completed a $3.914 billion acquisition of Edwards Lifesciences' Critical Care product group and executed a $2.0 billion accelerated share repurchase program in Q2 FY26, alongside retiring $2.1 billion of debt.

What is the strategic implication of Becton Dickinson's partnership with Quest Diagnostics for developing flow cytometry-based companion diagnostics?

Becton Dickinson's partnership with Quest Diagnostics for developing flow cytometry-based companion diagnostics strategically positions BD in the growing field of personalized medicine and advanced diagnostics. This collaboration leverages BD's expertise in flow cytometry to create targeted diagnostic tools for cancer and other diseases, enhancing its offerings in precision healthcare.

How does Becton Dickinson differentiate itself from competitors like Medtronic and Johnson & Johnson in the medical technology market?

Becton Dickinson differentiates itself from competitors like Medtronic and Johnson & Johnson through a deep focus on medical essentials, connected care, biopharma systems, and interventional solutions. While Medtronic and J&J offer broad portfolios, BD emphasizes transformative technologies and optimized clinical operations across its specialized segments, aiming to be a comprehensive partner for specific healthcare needs.

Powered by ForesightIQ · Competitive intelligence from digital exhaust